SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to ''Buyer and Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India''. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sun Pharma to announce third quarter results on January 31, 2024. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Record Date Fixed For Interim Dividend
February 9, 2024, is fixed as Record Date for Interim Dividend for FY 2023-24. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Quarterly Results And Interim Dividend
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 ,inter alia, to consider and approve This is to inform that the meeting of the Board of Directors of Sun Pharmaceutical Industries Limited is scheduled to be held on Wednesday, January 31, 2024, inter alia, 1. To consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2023 2. To consider and approve declaration of Interim Dividend for the financial year 2023-24 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per attached letter. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please refer the attached letter. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Investor Presentation
SPIL Investor Presentation January 2024 
Sun Pharma shares rise a percent to hit 52-week high, here's why
Sun Pharma stock has gained nearly 23.78% in the last six months and 29.28% in the last one year.